PCSA
Processa Pharmaceuticals Inc
NASDAQ · Pharmaceuticals
$2.38
+0.21 (+9.68%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.71M | 2.46M | 2.10M |
| Net Income | 319.8K | 302.9K | 327.4K |
| EPS | — | — | — |
| Profit Margin | 11.8% | 12.3% | 15.6% |
| Rev Growth | +2.4% | +0.4% | +18.3% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 1.15M | 1.26M | 1.21M |
| Total Equity | 4.18M | 3.59M | 4.27M |
| D/E Ratio | 0.28 | 0.35 | 0.28 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 521.3K | 563.7K | 431.6K |
| Free Cash Flow | 364.0K | 435.1K | 285.7K |